SMARCA2: The next big opportunity for degraders?

Now that targeted protein degraders have achieved clinical validation against established targets, companies are shifting focus to the modality’s primary value proposition: drugging the undruggable. Among once intractable targets gaining translational momentum, SMARCA2 stands out for its KRAS parallels and its potential to treat challenging solid tumors.

At this year’s American Association for Cancer Research (AACR) annual meeting, at least five companies published preclinical research supporting different targeted protein degrader designs against the chromatin remodeling protein. The jury is still out on which designs and E3 ligase targets are best suited for targeting SMARCA2. ...